One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects

Original Research

(2697) Views  (744) Full article downloads

Authors:

Monica Airoldi, Mauro Zaccarelli, Luca Bisi, et al

Published Date May 2010 Volume 2010:4 Pages 115 - 125

DOI: http://dx.doi.org/10.2147/PPA.S10330

Monica Airoldi^1,6, Mauro Zaccarelli², Luca Bisi³, Teresa Bini⁴, Andrea Antinori², Cristina Mussini³, Francesca Bai⁴, Giancarlo Orofino⁵, Laura Sighinolfi⁷, Andrea Gori⁶, Fredy Suter¹, Franco Maggiolo¹

¹Division of Infectious Diseases, Ospedali Riuniti, Bergamo; ²Clinical Department, INMI L Spallanzani, Roma; ³Division of Infectious Diseases, Università, Modena; ⁴Division of Infectious Diseases, Ospedale San Paolo, Milano; ⁵Division of Infectious Diseases, Ospedale Amedeo di Savoia, Torino; ⁶Division of Infectious Diseases, Ospedale San Gerardo, Monza; ⁷Division of Infectious Diseases, Ospedale Sant’Anna, Ferrara, Italy

Objective: The aim of the ADONE (ADherence to ONE pill) study was to verify the effect of a reduced number of pills on adherence and quality of life (QoL) in HIV-infected patients on highly active antiretroviral therapy (HAART).

Design: Prospective, multicenter, study.

Methods: Patients chronically treated with emtricitabine (FTC) + tenofovir (TDF) + efavirenz (EFV) or lamivudine (3TC) + TDF + EFV and with a HIV-RNA < 50 copies/mL were switched to the single-pill fixed-dose regimen (FDR) of FTC + TDF + EFV. Data were collected with SF-36 using visual analog scales. Results of the final (6 months) primary as-treated analysis are reported.

Results: 212 patients (77.4% males) of mean age 45.8 years were enrolled; 202 completed the study. One month post switch to FDR the adherence rate increased significantly to 96.1% from a baseline value of 93.8% (P < 0.01). The increase was steadily maintained throughout the study (96.2% at 6 months). QoL improved over time from 68.8% to 72.7% (P = 0.042) as well, and was significantly associated with the perception of health status, presence of adverse events (AEs) and number of reported AEs (P < 0.0001). QoL significantly influenced adherence (P < 0.0001). During FDR use the mean CD4 count increased from 556 to 605 cells/μL (P < 0.0001). At the end of follow-up 98% of patients maintained HIV-RNA level < 50 copies/mL and 100% <400 copies/mL. Four patients stopped therapy because they were lost to follow-up and 6 because of AEs (insomnia/nervousness 4, allergy 1, difficulties swallowing pills 1).

Conclusion: By substituting a one-pill once-a-day HAART, we observed an improvement of both adherence and QoL while maintaining high virologic and immunologic efficacy. HAART simplicity is an added value that favors adherence and may improve long-term success.

Keywords: EFV/FTC/TDF, single-pill regimen, once-daily antiretroviral regimen, adherence, QoL, patient preferences

Readers of this article also read: